高橋K、山谷S.定義された因子によるマウス胚および成体線維芽細胞培養からの多能性幹細胞の誘導。細胞。 2006; 126（4）：663–76。 https://doi.org/10.1016/j.cell.2006.07.024。
Avior Y、Sagi I、Benvenisty N.疾患モデリングおよび創薬における多能性幹細胞。 Nat Rev Mol Cell Biol。 2016; 17（3）：170–82。 https://doi.org/10.1038/nrm.2015.27。
バラチナL、アルシャギTE、オブライエンA、イヴァノフスカA、バリーF.フロントベットサイズ。 2023; 10：1176772。 https://doi.org/10.3389/fvets.2023.1176772。
農業と農村委員会、開発ep。 Equidae 2017の責任ある所有権とケアに関する報告 [Available from: https://www.europarl.europa.eu/doceo/document/A-8-2017-0014_EN.html#_part1_def9
Ribitsch I, Baptista PM, Lange-Consiglio A, Melotti L, Patruno M, Jenner F, et al. Large animal models in regenerative medicine and tissue engineering: to do or not to do. Front Bioeng Biotechnol. 2020;8:972. https://doi.org/10.3389/fbioe.2020.00972.
Kobold S, Bultjer N, Stacey G, Mueller SC, Kurtz A, Mah N. History and current status of clinical studies using human pluripotent stem cells. Stem Cell Rep. 2023;18(8):1592–8. https://doi.org/10.1016/j.stemcr.2023.03.005.
Peng J, Zhang WJ, Zhang Q, Su YH, Tang LP. The dynamics of chromatin States mediated by epigenetic modifications during somatic cell reprogramming. Front Cell Dev Biol. 2023;11:1097780. https://doi.org/10.3389/fcell.2023.1097780.
David L, Polo JM. Phases of reprogramming. Stem Cell Res. 2014;12(3):754–61. https://doi.org/10.1016/j.scr.2014.03.007.
Yu L, Wei Y, Sun HX, Mahdi AK, Pinzon Arteaga CA, Sakurai M, et al. Derivation of intermediate pluripotent stem cells amenable to primordial germ cell specification. Cell Stem Cell. 2021;28(3):550–e6712. https://doi.org/10.1016/j.stem.2020.11.003.
Zhang J, Zhao L, Fu Y, Liu F, Wang Z, Li Y, et al. Reprogramming efficiency and pluripotency of mule iPSCs over its parents. Biol Reprod. 2023;108(6):887–901. https://doi.org/10.1093/biolre/ioad041.
Spinelli V, Guillot PV, De Coppi P. Induced pluripotent stem (iPS) cells from human fetal stem cells (hFSCs). Organogenesis. 2013;9(2):101–10. https://doi.org/10.4161/org.25197.
Questa M, Moshref M, Jimenez RJ, Lopez-Cervantes V, Crawford CK, Settles ML, et al. Chromatin accessibility in canine stromal cells and its implications for canine somatic cell reprogramming. Stem Cells Transl Med. 2020;10(3):441–54. https://doi.org/10.1002/sctm.20-0278.
Eminli S, Foudi A, Stadtfeld M, Maherali N, Ahfeldt T, Mostoslavsky G, et al. Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells. Nat Genet. 2009;41(9):968–76. https://doi.org/10.1038/ng.428.
Pessôa LVF, Pires PRL, Del Collado M, Pieri NCG, Recchia K, Souza AF, et al. Generation and MiRNA characterization of equine induced pluripotent stem cells derived from fetal and adult multipotent tissues. Stem Cells Int. 2019;2019:1393791. https://doi.org/10.1155/2019/1393791.
Whitworth DJ, Ovchinnikov DA, Sun J, Fortuna PR, Wolvetang EJ. Generation and characterization of leukemia inhibitory factor-dependent equine induced pluripotent stem cells from adult dermal fibroblasts. Stem Cells Dev. 2014;23(13):1515–23. https://doi.org/10.1089/scd.2013.0461.
Tasma Z, Hou W, Damani T, Seddon K, Kang M, Ge Y, et al. Production of extracellular vesicles from equine embryo-derived mesenchymal stromal cells. Reproduction. 2022;164(4):143–54. https://doi.org/10.1530/rep-22-0215.
Merlo B, Teti G, Lanci A, Burk J, Mazzotti E, Falconi M, et al. Comparison between adult and foetal adnexa derived equine post-natal mesenchymal stem cells. BMC Vet Res. 2019;15(1):277. https://doi.org/10.1186/s12917-019-2023-5.
MacDonald ES, Barrett JG. The potential of mesenchymal stem cells to treat systemic inflammation in horses. Front Vet Sci. 2019;6:507. https://doi.org/10.3389/fvets.2019.00507.
Rim YA, Nam Y, Ju JH. Application of cord blood and cord blood-Derived induced pluripotent stem cells for cartilage regeneration. Cell Transpl. 2019;28(5):529–37. https://doi.org/10.1177/0963689718794864.
Guzzo RM, Scanlon V, Sanjay A, Xu RH, Drissi H. Establishment of human cell type-specific iPS cells with enhanced chondrogenic potential. Stem Cell Rev Rep. 2014;10(6):820–9. https://doi.org/10.1007/s12015-014-9538-8.
Bavin EP, Smith O, Baird AE, Smith LC, Guest DJ. Equine induced pluripotent stem cells have a reduced tendon differentiation capacity compared to embryonic stem cells. Front Vet Sci. 2015;2:55. https://doi.org/10.3389/fvets.2015.00055.
Quattrocelli M, Giacomazzi G, Broeckx SY, Ceelen L, Bolca S, Spaas JH, et al. Equine-Induced pluripotent stem cells retain lineage commitment toward myogenic and chondrogenic fates. Stem Cell Rep. 2016;6(1):55–63. https://doi.org/10.1016/j.stemcr.2015.12.005.
Koch TG, Heerkens T, Thomsen PD, Betts DH. Isolation of mesenchymal stem cells from equine umbilical cord blood. BMC Biotechnol. 2007;7:26. https://doi.org/10.1186/1472-6750-7-26.
Cequier A, Romero A, Vázquez FJ, Vitoria A, Bernad E, Fuente S, et al. Equine mesenchymal stem cells influence the proliferative response of lymphocytes: effect of Inflammation, differentiation and MHC-Compatibility. Anim (Basel). 2022;12(8). https://doi.org/10.3390/ani12080984.
Peffers MJ, Milner PI, Tew SR, Clegg PD. Regulation of SOX9 in normal and Osteoarthritic equine articular chondrocytes by hyperosmotic loading. Osteoarthritis Cartilage. 2010;18(11):1502–8. https://doi.org/10.1016/j.joca.2010.08.011.
Nagy K, Sung HK, Zhang P, Laflamme S, Vincent P, Agha-Mohammadi S, et al. Induced pluripotent stem cell lines derived from equine fibroblasts. Stem Cell Rev Rep. 2011;7(3):693–702. https://doi.org/10.1007/s12015-011-9239-5.
Shimada H, Nakada A, Hashimoto Y, Shigeno K, Shionoya Y, Nakamura T. Generation of canine induced pluripotent stem cells by retroviral transduction and chemical inhibitors. Mol Reprod Dev. 2010;77(1):2. https://doi.org/10.1002/mrd.21117.
Xu M, Stattin EL, Murphy M, Barry F. Generation of induced pluripotent stem cells (ARO-iPSC1-11) from a patient with autosomal recessive osteopetrosis harboring the c.212 + 1G > T mutation in SNX10 gene. Stem Cell Res. 2017;24:51–4. https://doi.org/10.1016/j.scr.2017.07.024.
Poon MW, He J, Fang X, Zhang Z, Wang W, Wang J, et al. Human ocular epithelial cells endogenously expressing SOX2 and OCT4 yield high efficiency of pluripotency reprogramming. PLoS ONE. 2015;10(7):e0131288. https://doi.org/10.1371/journal.pone.0131288.
Barrachina L, Remacha AR, Romero A, Vázquez FJ, Albareda J, Prades M, et al. Priming equine bone Marrow-Derived mesenchymal stem cells with Proinflammatory cytokines: implications in Immunomodulation-Immunogenicity Balance, cell Viability, and differentiation potential. Stem Cells Dev. 2017;26(1):15–24. https://doi.org/10.1089/scd.2016.0209.
de Castro RVG, Pieri NCG, Fantinato Neto P, Grizendi BM, Dória RGS, Meirelles FV, et al. In vitro induction of pluripotency from equine fibroblasts in 20% or 5% oxygen. Stem Cells Int. 2020;2020:8814989. https://doi.org/10.1155/2020/8814989.
Hauser S, Schuster S, Theurer Y, Synofzik M, Schöls L. Generation of optic atrophy 1 patient-derived induced pluripotent stem cells (iPS-OPA1-BEHR) for disease modeling of complex optic atrophy syndromes (Behr syndrome). Stem Cell Res. 2016;17(2):426–9. https://doi.org/10.1016/j.scr.2016.09.012.
Sharma R, Livesey MR, Wyllie DJ, Proudfoot C, Whitelaw CB, Hay DC, et al. Generation of functional neurons from feeder-free, keratinocyte-derived equine induced pluripotent stem cells. Stem Cells Dev. 2014;23(13):1524–34. https://doi.org/10.1089/scd.2013.0565.
Moro LN, Amin G, Furmento V, Waisman A, Garate X, Neiman G, et al. MicroRNA characterization in equine induced pluripotent stem cells. PLoS ONE. 2018;13(12):e0207074. https://doi.org/10.1371/journal.pone.0207074.
Petersen GF, Hilbert B, Trope G, Kalle W, Strappe P. Efficient transduction of equine adipose-derived mesenchymal stem cells by VSV-G pseudotyped lentiviral vectors. Res Vet Sci. 2014;97(3):616–22. https://doi.org/10.1016/j.rvsc.2014.09.004.
Breton A, Sharma R, Diaz AC, Parham AG, Graham A, Neil C, et al. Derivation and characterization of induced pluripotent stem cells from equine fibroblasts. Stem Cells Dev. 2013;22(4):611–21. https://doi.org/10.1089/scd.2012.0052.
Baird A, Barsby T, Guest DJ. Derivation of canine induced pluripotent stem cells. Reprod Domest Anim. 2015;50(4):669–76. https://doi.org/10.1111/rda.12562.
Guo L, Lin L, Wang X, Gao M, Cao S, Mai Y, et al. Resolving cell fate decisions during somatic cell reprogramming by Single-Cell RNA-Seq. Mol Cell. 2019;73(4):815–e297. https://doi.org/10.1016/j.molcel.2019.01.042.
Harman RM, Patel RS, Fan JC, Park JE, Rosenberg BR, Van de Walle GR. Single-cell RNA sequencing of equine mesenchymal stromal cells from primary donor-matched tissue sources reveals functional heterogeneity in immune modulation and cell motility. Stem Cell Res Ther. 2020;11(1):524. https://doi.org/10.1186/s13287-020-02043-5.
Bressan FF, Bassanezze V, de Figueiredo Pessôa LV, Sacramento CB, Malta TM, Kashima S, et al. Generation of induced pluripotent stem cells from large domestic animals. Stem Cell Res Ther. 2020;11(1):247. https://doi.org/10.1186/s13287-020-01716-5.
Baird A, Dominguez Falcon N, Saeed A, Guest DJ. Biocompatible Three-Dimensional printed thermoplastic scaffold for osteoblast differentiation of equine induced pluripotent stem cells. Tissue Eng Part C Methods. 2019;25(5):253–61. https://doi.org/10.1089/ten.TEC.2018.0343.
Yang F, Richardson DW. Comparative analysis of tenogenic gene expression in Tenocyte-Derived induced pluripotent stem cells and bone Marrow-Derived mesenchymal stem cells in response to biochemical and Biomechanical stimuli. Stem Cells Int. 2021;2021:8835576. https://doi.org/10.1155/2021/8835576.
Chung MJ, Park S, Son JY, Lee JY, Yun HH, Lee EJ, et al. Differentiation of equine induced pluripotent stem cells into mesenchymal lineage for therapeutic use. Cell Cycle. 2019;18(21):2954–71. https://doi.org/10.1080/15384101.2019.1664224.
Chen J, Liu H, Liu J, Qi J, Wei B, Yang J, et al. H3K9 methylation is a barrier during somatic cell reprogramming into iPSCs. Nat Genet. 2013;45(1):34–42. https://doi.org/10.1038/ng.2491.
Wu X, Dao Thi VL, Huang Y, Billerbeck E, Saha D, Hoffmann HH et al. Intrinsic Immunity Shapes Viral Resistance of Stem Cells. Cell. 2018;172(3):423 – 38.e25. https://doi.org/10.1016/j.cell.2017.11.018
Haas S, Trumpp A. An intrinsic interferon program protects stem cells from viral infection. Dev Cell. 2018;44(3):279–80. https://doi.org/10.1016/j.devcel.2018.01.013.
Ruiz S, Panopoulos AD, Herrerías A, Bissig K-D, Lutz M, Berggren WT, et al. A high proliferation rate is required for cell reprogramming and maintenance of human embryonic stem cell identity. Curr Biol. 2011;21(1):45–52. https://doi.org/10.1016/j.cub.2010.11.049.
Tobias IC, Kao MC, Parmentier T, Hunter H, LaMarre J, Betts DH. Targeted expression profiling reveals distinct stages of early canine fibroblast reprogramming are regulated by 2-oxoglutarate hydroxylases. Stem Cell Res Ther. 2020;11(1):528. https://doi.org/10.1186/s13287-020-02047-1.
Nantavisai S, Rodprasert W, Pathanachai K, Wikran P, Kitcharoenthaworn P, Smithiwong S, et al. Simvastatin enhances proliferation and pluripotent gene expression by canine bone marrow-derived mesenchymal stem cells (cBM-MSCs) in vitro. Heliyon. 2019;5(10):e02663. https://doi.org/10.1016/j.heliyon.2019.e02663.
Haridhasapavalan KK, Raina K, Dey C, Adhikari P, Thummer RP. An insight into reprogramming barriers to iPSC generation. Stem Cell Rev Rep. 2020;16(1):56–81. https://doi.org/10.1007/s12015-019-09931-1.
Gordeeva O. TGFβ Family Signaling Pathways in Pluripotent and Teratocarcinoma Stem Cells’ Fate Decisions: Balancing Between Self-Renewal, Differentiation, and Cancer. Cells. 2019;8(12). https://doi.org/10.3390/cells8121500.
Li Z, Ge W, Li Y, Zhang Y, Zhao X, Hu J. Valproic acid enhance reprogramming of bactrian camel cells through promoting the expression of endogenous gene c-Myc and the process of angiogenesis. Int J Stem Cells. 2021;14(2):191–202. https://doi.org/10.15283/ijsc20213.
Mullen AC, Wrana JL. TGF-β family signaling in embryonic and somatic Stem-Cell renewal and differentiation. Cold Spring Harb Perspect Biol. 2017;9(7). https://doi.org/10.1101/cshperspect.a022186.
Smith KP, Luong MX, Stein GS. Pluripotency: toward a gold standard for human ES and iPS cells. J Cell Physiol. 2009;220(1):21–9. https://doi.org/10.1002/jcp.21681.
Ezashi T, Yuan Y, Roberts RM. Pluripotent stem cells from domesticated mammals. Annu Rev Anim Biosci. 2016;4:223–53. https://doi.org/10.1146/annurev-animal-021815-111202.
Paterson YZ, Kafarnik C, Guest DJ. Characterization of companion animal pluripotent stem cells. Cytometry A. 2018;93(1):137–48. https://doi.org/10.1002/cyto.a.23163.
Su Y, Zhu J, Salman S, Tang Y. Induced pluripotent stem cells from farm animals. J Anim Sci. 2020. https://doi.org/10.1093/jas/skaa343.
Lee EM, Kim AY, Lee EJ, Park JK, Park SI, Cho SG, et al. Generation of Equine-Induced pluripotent stem cells and analysis of their therapeutic potential for muscle injuries. Cell Transpl. 2016;25(11):2003–16. https://doi.org/10.3727/096368916×691691.
Menon DV, Bhaskar S, Sheshadri P, Joshi CG, Patel D, Kumar A. Positioning canine induced pluripotent stem cells (iPSCs) in the reprogramming landscape of naïve or primed state in comparison to mouse and human iPSCs. Life Sci. 2021;264:118701. https://doi.org/10.1016/j.lfs.2020.118701.
Golipour A, David L, Liu Y, Jayakumaran G, Hirsch CL, Trcka D, et al. A late transition in somatic cell reprogramming requires regulators distinct from the pluripotency network. Cell Stem Cell. 2012;11(6):769–82. https://doi.org/10.1016/j.stem.2012.11.008.
Hotta A, Ellis J. Retroviral vector Silencing during iPS cell induction: an epigenetic beacon that signals distinct pluripotent States. J Cell Biochem. 2008;105(4):940–8. https://doi.org/10.1002/jcb.21912.
Palomino Lago E, Jelbert ER, Baird A, Lam PY, Guest DJ. Equine induced pluripotent stem cells are responsive to inflammatory cytokines before and after differentiation into musculoskeletal cell types. Vitro Cell Dev Biol Anim. 2023;59(7):514–27. https://doi.org/10.1007/s11626-023-00800-3.
#胚周産期および成体組織の細胞からの馬誘導多能性幹細胞の生成幹細胞の研究と療法